The Latest Analyst Ratings For Ionis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ:IONS) has received a range of analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased to $66.17. Analysts have adjusted their ratings and price targets based on recent developments, reflecting a positive outlook for the company despite some financial challenges.
July 16, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals has received predominantly bullish ratings from analysts over the past three months, with an average 12-month price target of $66.17. Analysts have raised their price targets, indicating a positive outlook despite recent financial challenges.
The majority of analysts have given bullish ratings, and the average price target has increased, suggesting a positive short-term impact on the stock price. Despite financial challenges, the raised price targets reflect confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100